Bristol Myers Squibb

Bristol Myers says new schizophrenia drug off to strong start Mint19:22

Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials PMLiVE12:44Arthritis Global Health

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval PMLiVE12:14FDA Cancer Treatment Cancer

Industry groups urge dismissal of prt lawsuit against Bristol-Myers Squibb Plansponsor.com22:07Pharma

This unpopular dividend stock is a buy The Motley Fool11:24S&P 500 Stock Markets (World) Stock Market (US)

Like Bristol-Myers Squibb and AbbVie, Johnson & Johnson seeks to bolster neuropsychiatric portfolio with $15 billion… Benzinga15:10Johnson and Johnson Pharma AbbVie

Cambridge Cognition highlights positive Cantab results PharmaTimes11:50Personality Disorder Pharma

Earnings preview: What to expect from Bristol-Myers Squibb's report Barchart16:19

From the Beatles to biologics – how Liverpool became a life science hotspot Yahoo! UK & Ireland06:13AstraZeneca UK Airports Pharma

Obesity treatments, m&a activity to take center stage during upcoming JPM healthcare conference Benzinga19:16JPMorgan Chase World Banking Tirzepatide

Latest News

In the last 6 hours

Industry Groups Urge Dismissal of PRT Lawsuit Against Bristol-Myers Squibb Plansponsor.com22:07 24-Jan-25

In the last 7 days

Notable Thursday Option Activity: BMY, YOU, DKS Nasdaq21:15 23-Jan-25

In the last month

Bristol Myers Squibb Foundation, Texas Children's Global HOPE, & Baylor College of Medicine… PR Newswire (Press Release)20:43 17-Jan-25

Earnings Preview: What To Expect From Bristol-Myers Squibb's Report Barchart16:19 15-Jan-25

Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a… Business Wire (Press Release)14:02 15-Jan-25

Bristol Myers Says New Schizophrenia Drug Off to Strong Start Mint19:22 14-Jan-25

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion… Benzinga15:10 13-Jan-25

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration … GlobeNewswire (Press Release)12:11 13-Jan-25

From the Beatles to biologics – how Liverpool became a life science hotspot Yahoo! UK & Ireland06:13 12-Jan-25

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? Nasdaq21:37 10-Jan-25

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference Benzinga19:16 9-Jan-25

Light Horse Therapeutics Debuts With $62 Million Series A Financing Business Wire (Press Release)14:07 9-Jan-25

This Unpopular Dividend Stock Is a Buy The Motley Fool11:24 9-Jan-25

Cambridge Cognition product used in schizophrenia treatment trial London South East14:29 8-Jan-25

Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials PMLiVE12:44 8-Jan-25

Cambridge Cognition highlights positive Cantab results PharmaTimes11:50 8-Jan-25

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval PMLiVE12:14 6-Jan-25

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy OncLive11:14 4-Jan-25

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade The Motley Fool10:20 4-Jan-25

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference Business Wire (Press Release)12:05 3-Jan-25

Profits slide at main Irish unit of drug giant Bristol Myers Squibb The Irish Times05:07 1-Jan-25

Profits down 42% at Irish arm of Bristol Myers Squibb RTE15:55 31-Dec-24

2 High-Yield Dividend Stocks to Buy Early in 2025 The Motley Fool12:52 31-Dec-24

Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F.… GlobeNewswire (Press Release)09:06 31-Dec-24

Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval Seeking Alpha20:08 30-Dec-24

Zolacabtagene autoleucel by Bristol-Myers Squibb for Follicular Lymphoma: Likelihood of Approval Pharmaceutical Technology19:44 30-Dec-24

Bristol-Myers Squibb’s Patent Expansion Plan May Run into Regulator Trouble TipRanks14:00 30-Dec-24

Brain Tumor Therapeutics Global Research Business Report 2024-2030 Featuring Profiles of Market … Business Wire (Press Release)13:57 30-Dec-24

FDA approves BMS’ Opdivo Qvantig for solid tumour indications Pharmaceutical Technology12:47 30-Dec-24

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for… PR Newswire (Press Release)11:33 30-Dec-24

Opdivo's subcutaneous PD-1 inhibitor cleared in US pharmaphorum09:17 30-Dec-24

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62 Simply Wall St20:08 29-Dec-24

AV Awards 2024: Retail Project of the Year – Bristol Myers Squibb, Cambridge Crossing Laboratory – LAB at Rockwell Group AV Interactive02:02 28-Dec-24

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy)… Business Wire (Press Release)22:39 27-Dec-24

Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Osteosarcoma: Likelihood of … Pharmaceutical Technology03:07 27-Dec-24

Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Sarcomas: Likelihood of… Pharmaceutical Technology03:07 27-Dec-24

view more headlines

24 Jan 22:07

Bristol Myers Squibb News

NewsNow brings you the latest news from the world’s most trusted sources on Bristol Myers Squibb. NewsNow aims to be the world’s most accurate and comprehensive Bristol Myers Squibb news aggregator, bringing you the latest headlines automatically and continuously 24/7.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.